Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Remission Is not Associated with DRD2 rs1800497 and DAT1 rs28363170 Genetic Variants in Male Schizophrenic Patients after 6-months Monotherapy with Olanzapine.

Psychiatria Danubina - 1 Jan 2020

Zivkovic Maja, Mihaljevic-Peles Alma, Muck-Seler Dorotea, Sagud Marina, Ganoci Lana, Vlatkovic Suzana, Tudor Lucija, Pivac Nela, Bozina Nada

Abstract excerpt

BACKGROUND: Symptomatic remission is an achievable goal in the treatment of schizophrenia. The type of antipsychotic medication and particular genetic variants of the dopaminergic system might be associated with remission. Potential pharmacogenetic markers of the treatment response to antipsychotic medication are missing. This study assessed the possible association between dopamine receptor type 2 (DRD2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to Dopamine Plasma Membrane Transport Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Olanzapine

Share to Receptors, Dopamine D2

Share to Schizophrenia

Share to Time Factors

Share to Treatment Outcome

Share to White People

Source

Identifiers

PMID: 32303037
DOI: 10.24869/psyd.2020.84

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 10 closest

Remission Is not Associated with DRD2 rs1800497 and DAT1 rs28363170 Genetic Variants in Male Schizophrenic Patients after 6-months Monotherapy with Olanzapine.PMID 32303037Read ↗

Anxiety symptom remission is associated with genetic variation of PTPRZ1 among patients with major depressive disorder treated with escitalopram.Semantic proximity Read ↗

P2RX7 polymorphisms Gln460Arg and His155Tyr are not associated with major depressive disorder or remission after SSRI or ECT.Semantic proximity Read ↗

Some dopaminergic genes polymorphisms are not associated with response to antipsychotic drugs in schizophrenic patients.Semantic proximity Read ↗

Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder.Semantic proximity Read ↗

Dopamine D4 receptor gene polymorphisms and neuroleptic response in schizophrenia.Semantic proximity Read ↗

Prediction of remission of depression with clinical variables, neuropsychological performance, and serotonergic/dopaminergic gene polymorphisms.Semantic proximity Read ↗

SLC6A2 variants may predict remission from major depression after venlafaxine treatment in Han Chinese population.Semantic proximity Read ↗

Prediction of the time-course pattern of remission in depression by using clinical, neuropsychological, and genetic variables.Semantic proximity Read ↗

No evidence for allelic association between schizophrenia and a functional variant of the human dopamine beta-hydroxylase gene (DBH).Semantic proximity Read ↗

No association between lithium full responders and the DRD1, DRD2, DRD3, DAT1, 5-HTTLPR and HTR2A genes in a Sardinian sample.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.